Is it Too Late to Buy United Airlines Stock?
United Airlines (NASDAQ:UAL) has thoroughly outpaced the broader stock market…
Buy
70
SBHMY Quote, Financials, Valuation and Earnings
Last price:
$9.38
Seasonality move
:
-1.22%
Day range:
$9.38 - $9.38
52-week range:
$6.69 - $9.65
Dividend yield:
2.19%
P/E ratio:
17.64x
P/S ratio:
2.14x
P/B ratio:
1.95x
Volume:
--
Avg. volume:
105
1-year change:
14.39%
Market cap:
$8.5B
Revenue:
$4B
EPS (TTM):
$0.53
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Sino Biopharmaceutical has -- downside to fair value with a price target of -- per share.
SBHMY vs. S&P 500
-
Over the past 5 trading days, Sino Biopharmaceutical has overperformed the S&P 500 by 6.68% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Sino Biopharmaceutical does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Sino Biopharmaceutical has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Sino Biopharmaceutical reported revenues of --.
Earnings Growth
-
Sino Biopharmaceutical has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Sino Biopharmaceutical reported earnings per share of --.
Enterprise value:
9.3B
EV / Invested capital:
--
Price / LTM sales:
2.14x
EV / EBIT:
12.04x
EV / Revenue:
2.32x
PEG ratio (5yr expected):
0.37x
EV / Free cash flow:
13.12x
Price / Operating cash flow:
10.48x
Enterprise value / EBITDA:
12.04x
Gross Profit (TTM):
$3.3B
Return On Assets:
5.38%
Net Income Margin (TTM):
12.13%
Return On Equity:
8.57%
Return On Invested Capital:
6.83%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2020-06-30 | 2021-06-30 | |
| Income Statement | ||||||
| Revenue | $3.5B | $3.5B | $2.4B | $906.2M | $1.1B | |
| Gross Profit | -- | -- | -- | $691.1M | $893.5M | |
| Operating Income | -- | -- | -- | $203.7M | $276.9M | |
| EBITDA | -- | -- | -- | $197.6M | $1.3B | |
| Diluted EPS | -- | -- | -- | $0.05 | $1.06 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $3.5B | -- | $3.8B | $3.4B | $3.4B | |
| Total Assets | $7.2B | -- | $9.3B | $9B | $9B | |
| Current Liabilities | $1.7B | -- | $2.9B | $3.2B | $2.7B | |
| Total Liabilities | $3.8B | -- | $3.8B | $3.6B | $3.1B | |
| Total Equity | $3.4B | -- | $5.5B | $5.4B | $5.9B | |
| Total Debt | -- | -- | $2B | $1.7B | $1.3B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2020-06-30 | 2021-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | $405.3M | $219.4M | $361.5M | |
| Cash From Investing | -- | -- | -- | -$216.3M | -$627.7M | |
| Cash From Financing | -- | -- | -- | $720.7M | -$117.9M | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
SBHMY
Sector
Market Cap
$8.5B
$37M
Price % of 52-Week High
97.2%
43.14%
Dividend Yield
2.19%
0%
Shareholder Yield
6.73%
-1.03%
1-Year Price Total Return
14.39%
-43.58%
Beta (5-Year)
0.412
0.746
Dividend yield:
2.19%
Annualized payout:
$0.15
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$9.02
200-day SMA
Buy
Level
$7.95
Bollinger Bands (100)
Buy
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Buy
Level
$8.44
Relative Strength Index (RSI14)
Buy
Level
89.98
ADX Line
Neutral
Level
0
Williams %R
Sell
Level
0
50-day SMA
Buy
Level
$7.99
MACD (12, 26)
Buy
Level
0.35
25-day Aroon Oscillator
Buy
Level
88
On Balance Volume
Neutral
Level
--
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
Buy
CA Score
(Annual)
Level (0.0271)
Buy
Beneish M-Score
(Annual)
Level (-2.546)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-1.9393)
Buy
Piotroski F Score
(Annual)
Level (4)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2024, 41.8% of the firm's total revenue comes from its innovative product category, which includes innovative drugs and biosimilar drugs. Sino Biopharm’s biggest revenue segment is oncology medicines, accounting for 37.2% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.
Stock Forecast FAQ
In the current month, SBHMY has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SBHMY average analyst price target in the past 3 months is --.
-
Where Will Sino Biopharmaceutical Stock Be In 1 Year?
According to analysts, the consensus estimate is that Sino Biopharmaceutical share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Sino Biopharmaceutical?
Analysts are divided on their view about Sino Biopharmaceutical share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Sino Biopharmaceutical is a Sell and believe this share price will rise from its current level to --.
-
What Is Sino Biopharmaceutical's Price Target?
The price target for Sino Biopharmaceutical over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SBHMY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Sino Biopharmaceutical is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of SBHMY?
You can purchase shares of Sino Biopharmaceutical via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Sino Biopharmaceutical shares.
-
What Is The Sino Biopharmaceutical Share Price Today?
Sino Biopharmaceutical was last trading at $9.38 per share. This represents the most recent stock quote for Sino Biopharmaceutical. Yesterday, Sino Biopharmaceutical closed at $9.38 per share.
-
How To Buy Sino Biopharmaceutical Stock Online?
In order to purchase Sino Biopharmaceutical stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
3 Smartest Dividend Stocks to Buy Now
When the market entered a correction in February and March,…
How High Could IBIT Go?
Recently, a surprising number of billionaire hedge fund managers have…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 37x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
42
Is NVDA Stock a Buy?
Market Cap: $2.6T
P/E Ratio: 37x
Alerts
Buy
100
DLICY alert for Apr 2
Dai-ichi Life Holdings [DLICY] is up 100.91% over the past day.
Buy
78
GATE alert for Apr 2
Marblegate Acquisition [GATE] is up 86.64% over the past day.
Sell
15
PCVX alert for Apr 2
Vaxcyte [PCVX] is down 14.62% over the past day.
